Type 2 diabetes
Conditions
Interventions
experimental group:dapagliflozin 10mg
Sponsors
The First Affiliated Hospital of Nanjing Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Diagnosed with T2DM; >= 18 years; body mass index > 18.5kg/m^2; 2. Glycated hemoglobin (HbA1c) 6-8%, stable blood sugar control; 3. The original oral hypoglycemic regimen has been used regularly for >=2 months and dapagliflozin has not been taken before; eGFR>30 ml/(min·1.73 m^2) with or without proteinuria. Approved by the hospital ethics committee, the patients signed the informed consent.
Exclusion criteria
Exclusion criteria: 1. Severe liver, kidney (eg: acute kidney injury) or heart disease (eg: hemodynamic instability, cardiac insufficiency NYHA grade 4, myocardial infarction, malignant arrhythmia, severe hypovolemia, etc.); Cancer; use of insulin; use of diuretics; T2DM complicated by acute complications of diabetes, infection, stress, etc.; history of previous recurrent urinary tract infection or genital infection; 2. Those who are not highly compliant with medicine and cannot follow the treatment plan; those who are pregnant or planning to become pregnant in the near future, and those who are breastfeeding.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| blood biochemistry;urinary electrolytes;glomerular filtration rate;bioelectrical impedance; | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse drug reactions and treatment-related complications; | — |
Countries
China
Contacts
Public ContactZhang Bo
Department of Nephrology, Jiangsu Provincial People's Hospital
Outcome results
None listed